EE05432B1 - Prroloprimidiinid kui valgukinaasi inhibiitorid - Google Patents
Prroloprimidiinid kui valgukinaasi inhibiitoridInfo
- Publication number
- EE05432B1 EE05432B1 EEP200400003A EEP200400003A EE05432B1 EE 05432 B1 EE05432 B1 EE 05432B1 EE P200400003 A EEP200400003 A EE P200400003A EE P200400003 A EEP200400003 A EE P200400003A EE 05432 B1 EE05432 B1 EE 05432B1
- Authority
- EE
- Estonia
- Prior art keywords
- rrolop
- rimidines
- protein kinase
- kinase inhibitors
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0115393.1A GB0115393D0 (en) | 2001-06-23 | 2001-06-23 | Chemical compounds |
US30167801P | 2001-06-28 | 2001-06-28 | |
PCT/GB2002/002835 WO2003000695A1 (en) | 2001-06-23 | 2002-06-21 | Pyrrolopyrimidines as protein kinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
EE200400003A EE200400003A (et) | 2004-02-16 |
EE05432B1 true EE05432B1 (et) | 2011-06-15 |
Family
ID=9917225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200400003A EE05432B1 (et) | 2001-06-23 | 2002-06-21 | Prroloprimidiinid kui valgukinaasi inhibiitorid |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP1404676A1 (et) |
JP (1) | JP4344607B2 (et) |
CN (1) | CN1294135C (et) |
AU (1) | AU2002314325B8 (et) |
BR (1) | BR0210652A (et) |
CA (1) | CA2451932C (et) |
CZ (1) | CZ20033443A3 (et) |
EA (1) | EA007415B1 (et) |
EC (1) | ECSP034922A (et) |
EE (1) | EE05432B1 (et) |
GB (1) | GB0115393D0 (et) |
HU (1) | HUP0400300A3 (et) |
ME (1) | MEP19308A (et) |
NZ (1) | NZ529766A (et) |
OA (1) | OA12632A (et) |
PL (1) | PL374096A1 (et) |
RS (1) | RS51698B (et) |
SK (1) | SK15882003A3 (et) |
TN (1) | TNSN03144A1 (et) |
TR (1) | TR200302242T2 (et) |
UA (1) | UA76760C2 (et) |
WO (1) | WO2003000695A1 (et) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0202679D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
IL166241A (en) | 2002-07-29 | 2011-12-29 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds for use in the treatment of autoimmune diseases |
EP1687309A1 (en) | 2003-11-17 | 2006-08-09 | Pfizer Products Inc. | Pyrrolopyrimidine compounds useful in treatment of cancer |
EP1689407A1 (en) * | 2003-11-25 | 2006-08-16 | Pfizer Products Inc. | Method of treatment of atherosclerosis |
US20050250829A1 (en) * | 2004-04-23 | 2005-11-10 | Takeda San Diego, Inc. | Kinase inhibitors |
FR2876103B1 (fr) | 2004-10-01 | 2008-02-22 | Aventis Pharma Sa | Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
DE602005023333D1 (de) | 2004-10-15 | 2010-10-14 | Takeda Pharmaceutical | Kinaseinhibitoren |
FR2878849B1 (fr) | 2004-12-06 | 2008-09-12 | Aventis Pharma Sa | Indoles substitues, compositions les contenant, procede de fabrication et utilisation |
WO2006135915A2 (en) | 2005-06-13 | 2006-12-21 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
EP2348023B9 (en) | 2005-12-13 | 2017-03-08 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
US20100120717A1 (en) | 2006-10-09 | 2010-05-13 | Brown Jason W | Kinase inhibitors |
CN101932582B (zh) | 2007-06-13 | 2013-09-25 | 因塞特公司 | 詹纳斯激酶抑制剂(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的盐 |
NZ586642A (en) | 2008-01-11 | 2012-04-27 | Natco Pharma Ltd | Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents |
DK2299821T3 (en) | 2008-06-10 | 2016-02-15 | Abbvie Inc | Tricyclic compounds |
CN102458581B (zh) | 2009-05-22 | 2016-03-30 | 因塞特控股公司 | 作为JANUS激酶抑制剂的吡唑-4-基-吡咯并[2,3-d]嘧啶和吡咯-3-基-吡咯并[2,3-d]嘧啶的N-(杂)芳基-吡咯烷衍生物 |
SG176111A1 (en) | 2009-05-22 | 2011-12-29 | Incyte Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
WO2011018894A1 (en) * | 2009-08-10 | 2011-02-17 | Raqualia Pharma Inc. | Pyrrolopyrimidine derivatives as potassium channel modulators |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
EP2485589A4 (en) | 2009-09-04 | 2013-02-06 | Biogen Idec Inc | HETEROARYARY INHIBITORS OF BTK |
RS56317B1 (sr) | 2009-12-01 | 2017-12-29 | Abbvie Inc | Nova triciklična jedinjenja |
ME02386B (me) | 2010-03-10 | 2016-09-20 | Incyte Holdings Corp | Derivati piperidin-4-il azetidina kao inhibitori jak1 |
KR102303885B1 (ko) | 2010-05-21 | 2021-09-24 | 인사이트 홀딩스 코포레이션 | Jak 저해제에 대한 국소 제형 |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
EP2640723A1 (en) | 2010-11-19 | 2013-09-25 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
CN102093364B (zh) * | 2011-01-07 | 2015-01-28 | 北京赛林泰医药技术有限公司 | 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物 |
CN103476776B (zh) * | 2011-01-07 | 2016-09-28 | 北京赛林泰医药技术有限公司 | 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物 |
US8691807B2 (en) | 2011-06-20 | 2014-04-08 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
CN104662018B (zh) | 2012-04-20 | 2017-10-24 | 阿迪维纳斯治疗有限公司 | 取代的杂双环化合物、组合物及其医疗应用 |
TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
WO2014015905A1 (en) | 2012-07-26 | 2014-01-30 | Glaxo Group Limited | 2 - (azaindol- 2 -yl) benz imidazoles as pad4 inhibitors |
CA2883894C (en) | 2012-09-06 | 2020-08-18 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
EA201590930A1 (ru) | 2012-11-15 | 2015-08-31 | Инсайт Корпорейшн | Лекарственные формы руксолитиниба с замедленным высвобождением |
JP6397831B2 (ja) | 2013-03-06 | 2018-09-26 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Jak阻害剤の製造方法及びその中間体 |
JP2016516710A (ja) | 2013-03-13 | 2016-06-09 | アッヴィ・インコーポレイテッド | ピリジン系cdk9キナーゼ阻害薬 |
EP2970268A1 (en) | 2013-03-13 | 2016-01-20 | AbbVie Inc. | Cdk9 kinase inhibitors |
CA2903538A1 (en) * | 2013-03-14 | 2014-10-02 | Abbvie Inc. | Pyrrolopyrimindine cdk9 kinase inhibitors |
WO2014151444A1 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors |
CA2905530A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors |
MY195091A (en) | 2013-08-07 | 2023-01-10 | Incyte Corp | Sustained Release Dosage Forms for a JAK1 Inhibitor |
CN104804001B9 (zh) * | 2014-01-24 | 2022-02-08 | 江苏柯菲平医药股份有限公司 | 4-取代吡咯并[2,3-d]嘧啶化合物及其用途 |
WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11780848B2 (en) | 2015-10-16 | 2023-10-10 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof |
US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
SG10201913986YA (en) | 2015-10-16 | 2020-03-30 | Abbvie Inc | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
US11564922B2 (en) | 2017-03-09 | 2023-01-31 | Abbvie Inc. | Methods of treating crohn's disease and ulcerative colitis |
MX2019010733A (es) | 2017-03-09 | 2019-11-01 | Abbvie Inc | Metodos para tratar la enfermedad de crohn y la colitis ulcerosa. |
WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
CR20200379A (es) | 2018-01-30 | 2021-03-05 | Incyte Corp | Procesos e intermedio para elaborar un inhibidor de jak campo técnico |
CA3095487A1 (en) | 2018-03-30 | 2019-10-03 | Incyte Corporation | Treatment of hidradenitis suppurativa using jak inhibitors |
AU2019353144B2 (en) | 2018-10-05 | 2023-11-16 | Annapurna Bio, Inc. | Compounds and compositions for treating conditions associated with APJ receptor activity |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0888349B1 (en) * | 1996-01-23 | 2002-05-22 | Novartis AG | Pyrrolopyrimidines and processes for their preparation |
JP2000505109A (ja) * | 1996-11-27 | 2000-04-25 | ファイザー・インク | 縮合二環式ピリミジン誘導体 |
PA8474101A1 (es) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
HUP0102574A3 (en) * | 1998-06-19 | 2002-01-28 | Pfizer Prod Inc | Pyrrolo[2,3-d]pyrimidine compounds |
WO2000017202A1 (en) * | 1998-09-18 | 2000-03-30 | Basf Aktiengesellschaft | 4-aminopyrrolopyrimidines as kinase inhibitors |
NZ518884A (en) * | 1999-12-10 | 2004-02-27 | Pfizer Prod Inc | Pyrrolo[2,3-d]pyrimidine compounds |
-
2001
- 2001-06-23 GB GBGB0115393.1A patent/GB0115393D0/en not_active Ceased
-
2002
- 2002-06-21 CA CA002451932A patent/CA2451932C/en not_active Expired - Fee Related
- 2002-06-21 PL PL02374096A patent/PL374096A1/xx not_active Application Discontinuation
- 2002-06-21 EP EP02740895A patent/EP1404676A1/en not_active Withdrawn
- 2002-06-21 SK SK1588-2003A patent/SK15882003A3/sk not_active Application Discontinuation
- 2002-06-21 HU HU0400300A patent/HUP0400300A3/hu unknown
- 2002-06-21 BR BR0210652-3A patent/BR0210652A/pt not_active Application Discontinuation
- 2002-06-21 UA UA2004010502A patent/UA76760C2/uk unknown
- 2002-06-21 EE EEP200400003A patent/EE05432B1/et not_active IP Right Cessation
- 2002-06-21 WO PCT/GB2002/002835 patent/WO2003000695A1/en active Application Filing
- 2002-06-21 AU AU2002314325A patent/AU2002314325B8/en not_active Ceased
- 2002-06-21 TN TNPCT/GB2002/002835A patent/TNSN03144A1/en unknown
- 2002-06-21 TR TR2003/02242T patent/TR200302242T2/xx unknown
- 2002-06-21 EA EA200400073A patent/EA007415B1/ru not_active IP Right Cessation
- 2002-06-21 NZ NZ529766A patent/NZ529766A/en not_active IP Right Cessation
- 2002-06-21 CZ CZ20033443A patent/CZ20033443A3/cs unknown
- 2002-06-21 OA OA1200300335A patent/OA12632A/en unknown
- 2002-06-21 JP JP2003507098A patent/JP4344607B2/ja not_active Expired - Fee Related
- 2002-06-21 CN CNB028119320A patent/CN1294135C/zh not_active Expired - Fee Related
- 2002-06-21 ME MEP-193/08A patent/MEP19308A/xx unknown
- 2002-06-21 RS YU99203A patent/RS51698B/en unknown
-
2003
- 2003-12-23 EC EC2003004922A patent/ECSP034922A/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2005508300A (ja) | 2005-03-31 |
EA007415B1 (ru) | 2006-10-27 |
JP4344607B2 (ja) | 2009-10-14 |
CN1518552A (zh) | 2004-08-04 |
NZ529766A (en) | 2008-11-28 |
CA2451932A1 (en) | 2003-01-03 |
OA12632A (en) | 2006-06-14 |
SK15882003A3 (sk) | 2004-07-07 |
RS51698B (en) | 2011-10-31 |
PL374096A1 (en) | 2005-09-19 |
GB0115393D0 (en) | 2001-08-15 |
TNSN03144A1 (en) | 2005-12-23 |
HUP0400300A3 (en) | 2010-12-28 |
EP1404676A1 (en) | 2004-04-07 |
MEP19308A (en) | 2010-06-10 |
RS99203A (en) | 2006-12-15 |
WO2003000695A1 (en) | 2003-01-03 |
ECSP034922A (es) | 2004-04-28 |
AU2002314325B2 (en) | 2009-01-08 |
EE200400003A (et) | 2004-02-16 |
UA76760C2 (uk) | 2006-09-15 |
EA200400073A1 (ru) | 2004-08-26 |
BR0210652A (pt) | 2004-08-10 |
CN1294135C (zh) | 2007-01-10 |
CA2451932C (en) | 2009-12-29 |
CZ20033443A3 (en) | 2004-03-17 |
TR200302242T2 (tr) | 2004-12-21 |
AU2002314325B8 (en) | 2009-01-29 |
HUP0400300A2 (en) | 2007-08-28 |
WO2003000695A8 (en) | 2004-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE05432B1 (et) | Prroloprimidiinid kui valgukinaasi inhibiitorid | |
NO20041887L (no) | Benzomidazoler anvendelige som proteinkinase-inhibitorer | |
DE60128709D1 (de) | Triazol-verbindungen als protein-kinase-inhibitoren | |
DE60129794D1 (de) | Pyrrol substituierte indolin-2-on protein kinase inhibitoren | |
EE200200140A (et) | Pteridinoonid kui kinaasi inhibiitorid | |
IS6968A (is) | Nýir týrósínkínasa tálmar | |
EE200300385A (et) | 3-(4-amidopürrool-2-üülmetülideen)-2-indolinooni derivaadid kui proteiini kinaasi inhibiitorid | |
DE60119776D1 (de) | Pyrazolverbindungen als protein-kinase-inhibitoren | |
ATE505471T1 (de) | Azaindol-kinaseinhibitoren | |
ID30460A (id) | Inhibitor-inhibitor protein siklik tirosin kinase | |
DK1370553T3 (da) | Rho-kinase-inhibitorer | |
DK1370552T3 (da) | Rho-kinase-inhibitorer | |
EE200300384A (et) | Kinasoliinid kui MMP-13 inhibiitorid | |
NO20035728D0 (no) | Pyrrolopyrimidiner som proteinkinaseinhibitorer | |
DE60101323D1 (de) | Tricyclische proteinkinasehemmer | |
IL151779A0 (en) | Protein tyrosine kinase inhibitors | |
IL145329A0 (en) | Protein tyrosine kinase inhibitors | |
DK1317448T4 (da) | Pyrazolforbindelser anvendelige som proteinkinaseinhibitorer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapsed by not paying the annual fees |
Effective date: 20120621 |